News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,089 Results
Type
Article (14028)
Company Profile (283)
Press Release (248778)
Section
Business (79426)
Career Advice (152)
Deals (13211)
Drug Delivery (34)
Drug Development (50364)
Employer Resources (31)
FDA (5696)
Job Trends (5120)
News (144240)
Policy (10021)
Tag
Academia (901)
Alliances (21595)
Alzheimer's disease (780)
Antibody-drug conjugate (ADC) (67)
Approvals (5682)
Artificial intelligence (84)
Bankruptcy (99)
Best Places to Work (4545)
Biotechnology (233)
Breast cancer (121)
Cancer (1018)
Cardiovascular disease (83)
Career advice (132)
CAR-T (83)
Cell therapy (242)
Clinical research (40371)
Collaboration (385)
Compensation (155)
COVID-19 (1016)
C-suite (100)
Cystic fibrosis (72)
Data (1058)
Diabetes (95)
Diagnostics (1218)
Earnings (29060)
Events (47398)
Executive appointments (310)
FDA (6125)
Funding (364)
Gene editing (70)
Gene therapy (181)
GLP-1 (330)
Government (1067)
Healthcare (6560)
Infectious disease (1057)
Inflammatory bowel disease (100)
IPO (7224)
Job creations (859)
Job search strategy (127)
Layoffs (192)
Legal (1378)
Lung cancer (151)
Manufacturing (93)
Medical device (2564)
Medtech (2565)
Mergers & acquisitions (6176)
Metabolic disorders (289)
Neuroscience (1066)
NextGen: Class of 2025 (2013)
Non-profit (850)
Northern California (1212)
Obesity (157)
Opinion (93)
Parkinson's disease (82)
Patents (68)
People (25244)
Phase I (14249)
Phase II (18771)
Phase III (11875)
Pipeline (449)
Postmarket research (852)
Preclinical (5979)
Radiopharmaceuticals (207)
Rare diseases (226)
Real estate (1411)
Regulatory (8362)
Research institute (932)
Series A (71)
Southern California (1090)
Startups (1968)
United States (9607)
Vaccines (175)
Weight loss (92)
Date
Today (37)
Last 7 days (269)
Last 30 days (1270)
Last 365 days (20375)
2025 (1222)
2024 (20553)
2023 (22414)
2022 (26824)
2021 (27805)
2020 (23357)
2019 (16228)
2018 (11738)
2017 (13746)
2016 (11846)
2015 (14354)
2014 (10395)
2013 (7486)
2012 (7533)
2011 (7619)
2010 (7430)
Location
Africa (146)
Asia (17025)
Australia (2877)
California (2760)
Canada (876)
China (252)
Colorado (104)
Connecticut (116)
Delaware (64)
Europe (36650)
Florida (311)
Georgia (80)
Illinois (175)
Indiana (67)
Maryland (364)
Massachusetts (2190)
Minnesota (112)
New Jersey (683)
New York (762)
North Carolina (445)
Northern California (1212)
Ohio (88)
Pennsylvania (530)
South America (207)
Southern California (1090)
Texas (310)
Washington State (267)
263,089 Results for "protagenic therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
November 6, 2024
·
3 min read
Business
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results
Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.
April 1, 2024
·
7 min read
Press Releases
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
October 29, 2024
·
3 min read
Business
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
Protagenic Therapeutics, Inc., a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to file that day, and its outlook for FY 2024.
March 25, 2024
·
2 min read
Drug Development
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
Protagenic Therapeutics, Inc. announced a step forward in its mission to address stress-related neuro-psychiatric disorders.
February 13, 2024
·
3 min read
Drug Development
Protagenic Therapeutics’ Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders
Protagenic Therapeutics, Inc., a leader in biopharmaceutical innovation, announced the complete safety data set from the single dose portion of its Phase 1 trial involving PT00114, its synthesized version of a natural stress-regulating brain peptide.
May 22, 2024
·
2 min read
Pharm Country
Protagenic Therapeutics Announces Date of Annual Shareholder Meeting
Protagenic Therapeutics, Inc. a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, announced its FY 2022 annual shareholder meeting will be held Wednesday, December 13, 2023, at 10:00 am EST, for shareholders of record as of this coming Monday, October 16th.
October 13, 2023
·
3 min read
Genetown
New Capital Strengthens ProtaGene’s Advanced Analytical Leadership in the Biologics and Cell and Gene Therapy Markets
ProtaGene, a leading global contract research organization dedicated to advanced analytics for biologics and cell and gene therapies, announced additional investment from Ampersand Capital Partners.
November 20, 2023
·
3 min read
Business
ProtaGene Appoints New Scientific and Commercial Leadership to Support Evolving Needs of Biologic and Cell & Gene Therapy Innovators
ProtaGene, GmbH, a leading global contract research organization focused on advanced analytics in biologics and cell and gene therapy, announced today the appointment of Jennifer Chadwick, Ph.D., as Chief Scientific Officer and Owen Hitchins as Chief Commercial Officer.
January 31, 2023
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
1 of 26,309
Next
